• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


Prices delayed by at least 15 minutes | Print

Live UK pricing:

Immupharma PLC (IMM)

ORD 1P
Sell: 3.205p|Buy: 3.805p|Change: 0.17 (-4.40%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPPand can be used with Dividend reinvestment

This investment is listed on the Alternative Investment Market (AIM). Investments on this market can be higher risk and have lower liquidity, meaning they can be harder to buy or sell, and their prices may be more volatile. Before investing, make sure you understand the risks of investing.

Company profile

ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.

Address

One Bartholomew Close
London
GBR
EC1A 7BL

Telephone

+44 2071524080

Website

https://www.immupharma.co.uk

Sector 

Healthcare

Forecast key dates

NameKey Date
ImmuPharma PLC Second Quarter Earnings Results for 20272027-09-15T00:00:00
ImmuPharma PLC Annual General Meeting for 20262027-06-25T10:00:00
ImmuPharma PLC Fourth Quarter Earnings Results for 20262027-05-27T00:00:00
ImmuPharma PLC Second Quarter Earnings Results for 20262026-09-15T00:00:00

Previous key dates

NameKey Date
ImmuPharma PLC Second Quarter Earnings Results for 20262026-09-15T00:00:00
ImmuPharma PLC Annual General Meeting for 20252026-06-25T10:00:00
ImmuPharma PLC Annual Report for 20252026-06-02T00:00:00
ImmuPharma PLC Fourth Quarter Earnings Results for 20252026-05-27T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.